The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Cortexyme Inc stock forecast from 0 analysts, the average analyst target price for Cortexyme Inc is not available over the next 12 months. Cortexyme Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cortexyme Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Cortexyme Inc’s stock price was USD 0.698. Cortexyme Inc’s stock price has changed by +1.01% over the past week, +1.16% over the past month and -44.60% over the last year.
No recent analyst target price found for Cortexyme Inc
No recent average analyst rating found for Cortexyme Inc
Company Overview Cortexyme Inc
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. Read Less
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative...Read More
Frequently Asked Questions About Cortexyme Inc (QNCX) Stock
Stock Target Advisor's fundamental analysis for Cortexyme Inc's stock is Bearish.
Unfortunately we do not have enough data on QNCX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on QNCX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on QNCX's stock to indicate if its overvalued.
The last closing price of QNCX's stock was USD 0.70.
The most recent market capitalization for QNCX is USD 0.03B.
Unfortunately we do not have enough analyst data on QNCX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cortexyme Inc's stock.
As per our most recent records Cortexyme Inc has 32 Employees.
Cortexyme Inc's registered address is 611 Gateway Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Cortexyme Inc's website at https://www.quincetx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Cortexyme Inc (QNCX) Stock
Stock Target Advisor's fundamental analysis for Cortexyme Inc's stock is Bearish.
Unfortunately we do not have enough data on QNCX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on QNCX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on QNCX's stock to indicate if its overvalued.
The last closing price of QNCX's stock was USD 0.70.
The most recent market capitalization for QNCX is USD 0.03B.
Unfortunately we do not have enough analyst data on QNCX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cortexyme Inc's stock.
As per our most recent records Cortexyme Inc has 32 Employees.
Cortexyme Inc's registered address is 611 Gateway Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Cortexyme Inc's website at https://www.quincetx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for QNCX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
